Search Results - "AMONKAR, M. M"

Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer by Riemsma, Rob, Forbes, C. A, Kessels, A, Lykopoulos, K, Amonkar, M. M, Rea, D. W, Kleijnen, J

“…To undertake a systematic review of three first-line treatments (letrozole, anastrozole and exemestane) for hormone sensitive advanced or metastatic breast…”
Get full text

Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial by Grob, Jean Jacques, Prof, Amonkar, Mayur M, PhD, Karaszewska, Boguslawa, MD, Schachter, Jacob, Prof, Dummer, Reinhard, Prof, Mackiewicz, Andrzej, Prof, Stroyakovskiy, Daniil, MD, Drucis, Kamil, MD, Grange, Florent, MD, Chiarion-Sileni, Vanna, MD, Rutkowski, Piotr, Prof, Lichinitser, Mikhail, Prof, Levchenko, Evgeny, MD, Wolter, Pascal, MD, Hauschild, Axel, Prof, Long, Georgina V, MD, Nathan, Paul, MD, Ribas, Antoni, Prof, Flaherty, Keith, MD, Sun, Peng, PhD, Legos, Jeffrey J, PhD, McDowell, Diane Opatt, MD, Mookerjee, Bijoyesh, MD, Schadendorf, Dirk, Prof, Robert, Caroline, MD

“…Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were…”
Get full text

Obesity and health-related quality of life: a cross-sectional analysis of the US population by HASSAN, M. K, JOSHI, A. V, MADHAVAN, S. S, AMONKAR, M. M

“…To examine the relationship between body mass index (BMI) and health-related quality-of-life (HRQL), in the presence of dietary controls and/or exercise in a…”
Get full text

Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis by Cramer, Joyce A., Amonkar, Mayur M., Hebborn, Ansgar, Altman, Roy

“…ABSTRACT Objective: Poor compliance and persistence with bisphosphonates is a concern in postmenopausal osteoporosis due to its negative impact on fracture…”
Get full text

Health-related quality of life in patients treated with pembrolizumab for microsatellite instability–high/mismatch repair–deficient advanced solid tumours: Results from the KEYNOTE-158 study by Maio, Michele, Amonkar, Mayur M., Norquist, Josephine M., Ascierto, Paolo A., Manzyuk, Ludmila, Motola-Kuba, Daniel, Penel, Nicolas, Cassier, Philippe A., Bariani, Giovanni M., De Jesus Acosta, Ana, Doi, Toshihiko, Longo, Federico, Miller, Wilson H., Oh, Do-Youn, Gottfried, Maya, Wang, Ruixue, Norwood, Kevin, Marabelle, Aurelien

“…In the KEYNOTE-158 study (NCT02628067), pembrolizumab showed a high objective response rate and durable clinical benefit for patients with previously treated,…”
Get full text

Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study by Schadendorf, D., Amonkar, M.M., Milhem, M., Grotzinger, K., Demidov, L.V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J.C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F.S., Patel, K., Casey, M., Robert, C.

“…In a randomized phase III study, trametinib prolonged progression-free survival and improved overall survival versus chemotherapy in patients with BRAF V600…”
Get full text

Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine by Grob, J.-J., Amonkar, M.M., Martin-Algarra, S., Demidov, L.V., Goodman, V., Grotzinger, K., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., Miller, W.H., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S., Hauschild, A.

“…In a randomized phase III study (BREAK-3), dabrafenib showed prolonged progression-free survival (PFS) (median 5.1 versus 2.7 months; hazard ratio = 0.30; 95%…”
Get full text

Health-related quality of life with pembrolizumab monotherapy in patients with previously treated advanced microsatellite instability high/mismatch repair deficient endometrial cancer in the KEYNOTE-158 study by O'Malley, D.M., Bariani, G.M., Cassier, P.A., Marabelle, A., Hansen, A.R., De Jesus Acosta, A., Miller, W.H., Safra, T., Italiano, A., Mileshkin, L., Amonkar, M., Yao, L., Jin, F., Norwood, K., Maio, M.

“…OBJECTIVEPembrolizumab demonstrated a clinically meaningful objective response rate in patients with previously treated, advanced MSI-H/dMMR endometrial cancer…”
Get full text

Clinical outcomes of chemotherapy-based therapies for previously treated advanced colorectal cancer: a systematic literature review and meta-analysis by Amonkar, Mayur M., Abderhalden, Lauren A., Frederickson, Andrew M., Aksomaityte, Audrone, Lang, Brian M., Leconte, Pierre, Zhang, Ina

“…Purpose The purpose of this study was to evaluate clinical outcomes of standard therapies in previously treated, advanced colorectal cancer (CRC) patients…”
Get full text

Clinical Outcomes for Previously Treated Patients with Advanced Gastric or Gastroesophageal Junction Cancer: A Systematic Literature Review and Meta-Analysis by Abderhalden, Lauren A., Wu, Ping, Amonkar, Mayur M., Lang, Brian M., Shah, Sukrut, Jin, Fan, Frederickson, Andrew M., Mojebi, Ali

“…Purpose Although second-line treatments improve survival compared to best supportive care in patients with advanced gastric cancer with disease progression on…”
Get full text

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer by Wu, Y, Amonkar, M M, Sherrill, B H, O'Shaughnessy, J, Ellis, C, Baselga, J, Blackwell, K L, Burstein, H J

Get full text

Adherence with colorectal cancer screening guidelines: a review by Subramanian, Sujha, Klosterman, Michelle, Amonkar, Mayur M, Hunt, Timothy L

“…Objective. To review screening rates and factors impacting patient utilization of colorectal cancer screening tests. Methods. We searched Medline, CancerLit,…”
Get full text

Primary culture of tracheal aspirate-derived human airway basal stem cells by Amonkar, Gaurang M., Wagner, Richard, Bankoti, Kamakshi, Shui, Jessica E., Ai, Xingbin, Lerou, Paul H.

“…Patient-specific airway basal stem cells (BSCs) can be derived from tracheal aspirate (TA) samples from intubated patients, thus providing an invaluable lung…”
Get full text

Real-world treatment patterns and clinical outcomes for chemotherapy-based regimens in first-line MSI-H/dMMR metastatic colorectal cancer by Amonkar, Mayur M., Chase, Monica, Myer, Nicole M., Wang, Tongtong, Turzhitsky, Vladimir, Spira, Alexander

“…•Real-world treatment patterns and clinical outcomes for first line, stage IV MSI-H/dMMR CRC were assessed.•Study included patients from a US oncology network…”
Get full text

Assessing the Economic Burden of Adverse Effects (AES) Associated with Metastatic Melanoma (MM) Treatments in Germany by Vouk, K, Amonkar, M, Benter, U

Get full text

Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer by Sherrill, B, Amonkar, M, Wu, Y, Hirst, C, Stein, S, Walker, M, Cuzick, J

“…The relationship between overall survival (OS) and disease progression end points has been demonstrated in colorectal, colon, and non-small cell lung cancers…”
Get full text

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer by Wu, Y., Amonkar, M.M., Sherrill, B.H., O’Shaughnessy, J., Ellis, C., Baselga, J., Blackwell, K.L., Burstein, H.J.

“…Progression-free survival (PFS) was significantly longer for the lapatinib plus trastuzumab (L+T) arm than for L alone in a phase III, randomized, open-label…”
Get full text

Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer by Sherrill, B, Amonkar, M M, Stein, S, Walker, M, Geyer, C, Cameron, D

“…The addition of lapatinib (Tykerb/Tyverb) to capecitabine (Xeloda) delays disease progression more effectively than capecitabine monotherapy in women with…”
Get full text

Adjusting for Treatment Crossover in A Trametinib Metastatic Melanoma Rct: Identifying the Appropriate Method by Bell, H, Latimer, N, Amonkar, M, Casey, M

Get full text

Cost Burden of Adverse Effects Associated with Metastatic Melanoma (MM) Therapies in Australia by Benter, U, Amonkar, M, Vouk, K

Get full text